Dyax Corp. to Participate in the Jefferies 2015 Global Healthcare Conference
May 27 2015 - 8:00AM
Business Wire
Dyax Corp. (NASDAQ: DYAX) announced today that executive
management will participate in the Jefferies 2015 Global Healthcare
Conference being held June 1-4, 2015 at the Grand Hyatt in New York
City. The Company is scheduled to present on Monday, June 1 at
3:00pm (ET) and will provide an update on DX-2930, KALBITOR®
(ecallantide) and the Licensing and Funded Research Portfolio
(LFRP).
This presentation will be webcast live and may be accessed by
visiting the Investor Relations section of the company’s website at
http://investor.dyax.com/events.cfm. The webcast will also be
available on the Dyax website for a limited period of time
following the conference.
About DyaxDyax is a biopharmaceutical company focused on
the development and commercialization of novel biotherapeutics for
unmet medical needs. The Company is developing DX-2930, a fully
human monoclonal antibody, for the prevention of hereditary
angioedema (HAE) attacks. In March 2015, the Company reported
positive safety, pharmacokinetic, biomarker and proof-of-concept
efficacy results from its Phase 1b clinical trial of DX-2930 in HAE
patients. Additionally, Dyax markets KALBITOR® (ecallantide) for
the treatment of acute attacks of HAE in patients 12 years of age
and older.
Both DX-2930 and KALBITOR were identified using Dyax's
proprietary phage display technology. Dyax has broadly licensed
this technology under its LFRP. The current portfolio includes one
FDA approved product, Eli Lilly and Company’s CYRAMZA®
(ramucirumab), for which Dyax receives royalties, and multiple
product candidates in various stages of clinical development for
which the Company is eligible to receive future milestones and/or
royalties.
For additional information about Dyax, please visit www.dyax.com.
For additional information about KALBITOR, including full
prescribing information, please visit www.KALBITOR.com.
DisclaimerThis press release contains forward-looking
statements. Statements that are not historical facts are based on
Dyax's current expectations, beliefs, assumptions, estimates,
forecasts and projections about the industry and markets in which
Dyax operates. The statements contained in this release are not
guarantees of future performance and involve certain risks,
uncertainties and assumptions, which are difficult to predict.
Therefore, actual outcomes and results may differ materially from
what is expressed in such forward-looking statements because of
risks, uncertainties and assumptions involved in any future
projections. There are many factors that could cause actual results
to differ from these forward-looking statements, including: risks
and uncertainties relating to the clinical development and
regulatory approval of DX-2930; Dyax's dependence on the expertise,
effort, priorities and contractual obligations of third parties in
the development of DX-2930 and in the marketing, sales and
distribution of KALBITOR; competition from new and existing
treatments for HAE; the uncertainty of patent and intellectual
property protection relating to DX-2930, KALBITOR and the LFRP;
Dyax's dependence on licensees and collaborators for development,
clinical trials, manufacturing, sales and distribution of product
candidates in the LFRP; uncertainties as to whether one or more
product candidates in the LFRP will achieve development and
regulatory milestones and be commercialized and generate royalties;
uncertainties regarding Lilly's ability to successfully market
CYRAMZA for the treatment of advanced gastric cancer; and other
risk factors described or referred to in Item 1A, "Risk Factors" in
Dyax's most recent Annual Report on Form 10-K and other periodic
reports filed with the Securities and Exchange Commission. Dyax
cautions investors not to place undue reliance on the
forward-looking statements contained in this release. These
statements speak only as of the date of this release, and Dyax
undertakes no obligations to update or revise these statements,
except as may be required by law.
Dyax, the Dyax logo and KALBITOR are registered trademarks of
Dyax Corp.CYRAMZA is a trademark owned by or licensed to Eli Lilly
and Company, its subsidiaries, or affiliates.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150527005284/en/
Dyax Corp.Jennifer Robinson, 617-250-5741Director, Investor
Relations and Corporate Communicationsjrobinson@dyax.com
Dyax (NASDAQ:DYAX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dyax (NASDAQ:DYAX)
Historical Stock Chart
From Apr 2023 to Apr 2024